TGFBR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL94423	0.43	5/20
Plx-4720 (SCHEMBL133733)	1.00	2/20
Vemurafenib (SCHEMBL298931)	1.00	2/20
SCHEMBL298368	0.91	2/20
SCHEMBL298760	0.90	2/20
SCHEMBL298198	0.88	2/20
SCHEMBL293053	0.88	2/20
SCHEMBL298626	0.87	2/20
SCHEMBL299099	0.86	2/20
SCHEMBL298282	0.84	2/20
SCHEMBL298379	0.84	2/20
SCHEMBL298349	0.83	2/20
SCHEMBL293377	0.83	2/20
SCHEMBL298613	0.82	2/20
SCHEMBL294160	0.82	2/20
SCHEMBL294126	0.81	2/20
SCHEMBL297768	0.80	2/20
SCHEMBL298366	0.80	2/20
SCHEMBL298547	0.80	2/20
SCHEMBL298825	0.80	2/20

Clinical trials — most relevant to TGFBR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)	PHASE4	COMPLETED
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients	PHASE3	UNKNOWN
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C	PHASE3	COMPLETED
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).	PHASE2	COMPLETED
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor	PHASE1/PHASE2	COMPLETED
Safety and Imaging Study of GC1008 in Glioma	PHASE2	COMPLETED
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers	PHASE1/PHASE2	COMPLETED
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma	PHASE2	COMPLETED
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta Trap/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)	PHASE1/PHASE2	COMPLETED
Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer	PHASE2	WITHDRAWN
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA	PHASE1	COMPLETED
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD	PHASE1	COMPLETED
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2	PHASE1	COMPLETED
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies	PHASE1	RECRUITING
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis	nan	UNKNOWN
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension	nan	UNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
Biomarker Levels During Indwelling Pleural cAtheter Sample Testing	nan	ENROLLING_BY_INVITATION
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention	nan	UNKNOWN
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)	nan	UNKNOWN
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
Vitamin D Deficiency and Effect of Its Supplementation on Interstitial Lung Diseases(ILD).	nan	UNKNOWN
Klotho _ LRP-6 _ Gastric Adenocarcinoma	nan	UNKNOWN
Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension	nan	ACTIVE_NOT_RECRUITING
Magnetic Resonance Imaging:A Window to Anthracycline Toxicity	nan	COMPLETED
Luspatercept in Metastatic AGCT of the Ovary	nan	COMPLETED
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases	nan	NOT_YET_RECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TGFBR2 binder may also engage these)

Protein	Name	Similarity
P38438	—	1.000	P38438 →
Q90999	—	1.000	Q90999 →
Q62312	—	1.000	Q62312 →
Q90669	—	0.982	Q90669 →
P38444	—	0.980	P38444 →
P27039	—	0.979	P27039 →
Q28043	—	0.977	Q28043 →
P27038	—	0.977	P27038 →
ACVR2A	Activin receptor type-2A	0.976	landscape →
Q9ESL4	—	0.975	Q9ESL4 →
MAP3K20	Mitogen-activated protein kinase kinase kinase 20	0.971	landscape →
Q28560	—	0.970	Q28560 →
NTRK2	BDNF/NT-3 growth factors receptor	0.969	landscape →
P00534	—	0.968	P00534 →
Q3LAC4	—	0.966	Q3LAC4 →
Q01887	—	0.966	Q01887 →
Q63604	—	0.966	Q63604 →
P34925	—	0.965	P34925 →
P15209	—	0.964	P15209 →
Q5GIG6	—	0.964	Q5GIG6 →
P27041	—	0.963	P27041 →
Q3UGM2	—	0.963	Q3UGM2 →
Q8QZR7	—	0.962	Q8QZR7 →
TNNI3K	Serine/threonine-protein kinase TNNI3K	0.962	landscape →
NEK10	Serine/threonine-protein kinase Nek10	0.961	landscape →
P00535	—	0.961	P00535 →
PRKD1	Serine/threonine-protein kinase D1	0.960	landscape →
Q91044	—	0.960	Q91044 →
Q03351	—	0.959	Q03351 →
Q8N165	—	0.959	Q8N165 →